Ausschlusskriterien
Any prior ocular (in the study eye) or systemic treatment or surgery for neovascular AMD, except dietary supplements or vitamins.
boolean
Any prior or concomitant therapy with another investigational agent to treat neovascular AMD in the study eye.
boolean
Any prior treatment with anti-VEGF agents in the study eye.
boolean
Total lesion size >12 disc areas (30.5 mm, including blood, scars and neovascularization) as assessed by FA in the study eye.
boolean
Subretinal hemorrhages that is either 50% or more of the total lesion area, or if the blood is under the fovea and is 1 or more disc areas in size in the study eye (if the blood is under the fovea, then the fovea must be surrounded by 270 degrees by visible CNV).
boolean
Scar or fibrosis making up >50% of the total lesion in the study eye.
boolean
Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.
boolean
Presence of retinal pigment epithelial tears or rips involving the macula in the study eye.
boolean
History of any vitreous hemorrhage within 4 weeks prior to Visit 1 in the study eye.
boolean
Presence of other causes of CNV in the study eye.
boolean
Prior vitrectomy in the study eye.
boolean
History of retinal detachment or treatment or surgery for retinal detachment in the study eye.
boolean
Any history of macular hole of stage 2 and above in the study eye.
boolean
Any intraocular or periocular surgery within 3 months of Day 1 on the study eye, except lid surgery, which may not have taken place within 1 month of Day 1, as long as it is unlikely to interfere with the injection.
boolean
History or clinical evidence of diabetic retinopathy, diabetic macular edema or any retinal vascular disease other than AMD in either eye.
boolean